Dr. Burke on Findings of GOYA Study for Diffuse Large B-Cell Lymphoma

John M. Burke, MD
Published: Friday, Feb 24, 2017



John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

In terms of efficacy and progression-free survival, the 2 arms of the study were similar. The obinutuzumab arm experienced more toxicity, such as the lowering of neutrophil and platelet counts.

It did not appear that replacing rituximab (Rituxan) with obinutuzumab provided an advantage in patients with DLBCL, Burke explains.
 


John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

In terms of efficacy and progression-free survival, the 2 arms of the study were similar. The obinutuzumab arm experienced more toxicity, such as the lowering of neutrophil and platelet counts.

It did not appear that replacing rituximab (Rituxan) with obinutuzumab provided an advantage in patients with DLBCL, Burke explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x